Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linvoseltamab Dosing De-Escalation in Relapsed Multiple Myeloma
NCT07181941Phase 2Recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Mar 2026
- Primary completion
- Jun 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of linvoseltamab in multiple myeloma (MM), sponsored by Fred Hutchinson Cancer Center. Started Mar 2026; status: recruiting.
02
Drugs
linvoseltamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07181941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07181941.